This segment focuses on the key efficacy data on progression-free survival, response rates, and duration of response from MARIPOSA-2.
Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC
Pooled results from the TRUST-I and TRUST-II trials showed that taletrectinib led to infrequent neurological TEAEs in patients with ROS1-positive NSCLC.
Improving NSCLC Surgery Recovery After Climate Disaster Exposure
The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.
Plasma-Based MRD Analysis May Predict Recurrence in EGFR-Mutant NSCLC
A disease-free survival and minimal residual disease event-free status was maintained for most patients with adjuvant osimertinib for EGFR-mutant NSCLC.
Navigating Management and Dosing Considerations for Amivantamab in NSCLC
Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.
EU’s CHMP Recommends Approving Perioperative Nivolumab Combo in NSCLC
Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.
Osimertinib Shows Sustained Survival Benefit in EGFR-Mutant NSCLC
The safety profiles of osimertinib monotherapy and combination therapy were consistent with prior reports in EGFR-mutated non–small cell lung cancer.